Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2003

View Archived Issues

Novel agents for gastroesophageal reflux disease identified at AstraZeneca

Evidence of antitumor activity found for Xyotax in recurrent ovarian cancer

Elan and Pharmacia present novel beta-secretase inhibitors for AD and other disorders

Orally active analgesics with minimal stimulant effects discovered at Dainippon

Grelan researchers prepare and test new naphthyridine-based PDE4 inhibitors

Novel PPAR agonists identified by Eisai scientists

Fuji Yakuhin identifies new series of antitumor agents

Selective, small-molecule inhibitor of AKT kinase activity induces apoptosis in cancer cells

Texas Biotechnology to reacquire full sitaxsentan rights

Toray and Fujisawa to codevelop TRK-820 in Europe

New Bcl-2/Bcl-XL inhibitor may facilitate chemotherapy in resistant ovarian cancer

GenoMed evaluates intravenous drug regimen for acute kidney failure

Sunesis awarded SBIR grant for novel kinase inhibitor drug discovery

Recent accomplishments at Icos

Docetaxel followed by NS-398 results in additive apoptotic effect in ovarian cancer cells

ATN-161 enters the clinic

Corixa and GSK form cancer vaccine collaboration

Phase IIb trial of eculizumab in rheumatoid arthritis completes enrollment

Catholic University of Louvain to terminate agreement with BioTransplant

French researchers identify potent and selective 5-HT4 antagonist/partial agonist

BioSante signs malaria vaccine CRADA with U.S. Navy

Ivax to develop immunotoxin to treat HIV

New Japanese pharmaceutical company begins operations

FDA accepts memantine filing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...